/GRAY

GRAY Stock - Graybug Vision, Inc.

Q: What is the analyst price target for GRAY?

Analyst price target information is not currently available for GRAY.

Q: What is GRAY's market cap?

Market capitalization information is not currently available for GRAY.

Healthcare|Biotechnology|NASDAQ

$5.50-10.80%

$0.67 (-10.80%) • Mar 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+406.0%upside

Target: $27.83

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for GRAY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.20

52W High$20.30

52W Low$4.88

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$2.96M	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-24,204,000	$-36,180,000	$-35,947,000	$-29,832,000	$-37,502,000
Net Income	$-13,700,000	$-35,605,000	$-35,821,000	$-27,531,000	$-36,644,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.22	$-23.24	$-22.34	$-57.10	$-35.47

Company Overview

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

Visit Website

Earnings History & Surprises

GRAY

Beat Rate

Last 11 quarters

Avg Surprise

-1241.5%

EPS vs Estimate

Beats / Misses

1/10

Last 12 quarters

Latest EPS

$-15.88

Q2 2023

EPS Surprise History

Q3 21

-972.3%

$-5.04vs$-0.47

Q4 21

-1337.8%

$-5.32vs$-0.37

Q1 22

-1451.4%

$-5.74vs$-0.37

Q2 22

-1668.4%

$-6.72vs$-0.38

Q3 22

-1230.0%

$-5.32vs$-0.40

Q4 22

-1363.6%

$-6.44vs$-0.44

Q1 23

+8.9%

$-0.41vs$-0.45

Q2 23

-3428.3%

$-15.88vs$-0.45

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 6, 2024	—	—	—	—
Q4 2023	Nov 8, 2023	—	—	—	—
Q3 2023	Aug 9, 2023	$-0.45	—	—	—
Q2 2023	May 8, 2023	$-0.45	$-15.88	-3428.3%	✗ MISS
Q1 2023	Mar 9, 2023	$-0.45	$-0.41	+8.9%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.44	$-6.44	-1363.6%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.40	$-5.32	-1230.0%	✗ MISS
Q2 2022	May 10, 2022	$-0.38	$-6.72	-1668.4%	✗ MISS
Q1 2022	Mar 10, 2022	$-0.37	$-5.74	-1451.4%	✗ MISS
Q4 2021	Nov 11, 2021	$-0.37	$-5.32	-1337.8%	✗ MISS
Q3 2021	Aug 11, 2021	$-0.47	$-5.04	-972.3%	✗ MISS
Q2 2021	May 12, 2021	$-0.44	$-7.56	-1618.2%	✗ MISS
Q1 2021	Mar 4, 2021	$-0.40	$-1.38	-245.0%	✗ MISS
Q4 2020	Nov 12, 2020	$-0.56	$-2.52	-350.0%	✗ MISS
Q3 2020	Sep 25, 2020	—	$-0.31	—	—
Q1 2020	Mar 31, 2020	—	$-0.54	—	—
Q4 2019	Dec 31, 2019	—	$-0.71	—	—
Q3 2019	Sep 30, 2019	—	$-0.71	—	—